**References**

[[1]](#endnote-1)1. Unpublished Clinical Reference Laboratory data, 2011.

[[2]](#endnote-2)2. Stout RL, Fulks M, Dolan VF. Beware that Low Urine Creatinine! *On The Risk - Journal of the Academy of Life Underwriting* 2014;30(1):48-53.

[[3]](#endnote-3)3. Fulks, M. Stout RL, Dolan VF. Urine Protein/Creatinine Ratio as a Mortality Risk Predictor in Non-diabetics with Normal Renal Function. *J Insur Med*. 2012;43(2): 76-83.

4. Stout RL, Fulks M, Dolan VF, Magee ME, Suarez, L. Relationship of Hemoglobin A1c to Mortality in Nonsmoking Insurance Applicants. *J Insur Med*. 2007;39:174-81.

5. Dolan VF, Stout RL, Fulks M. Hemoglobin A1c and Mortality in Insurance Applicants: A 5-Year Follow-Up Study. *On The Risk - Journal of the Academy of Life Underwriting*. 2009;25(1):42-9.

6. Dolan VF, Stout RL, Fulks M. Glucosuria as a Mortality Risk Predictor When Blood Is Not Collected. *On The Risk - Journal of the Academy of Life Underwriting*. 2010;26(2):46-51.

7. Dolan VF, Stout RL, Fulks M. [Isolated Hematuria as a Mortality Risk Predictor.](http://www.crlcorp.com/wp-content/uploads/2013/06/otr_-_hematuria_and_mortality_2011.pdf) *On The Risk - Journal of the Academy of Life Underwriting*. 2011;27(4):30-5.

8. Accidental Deaths Center for Disease Control and Prevention, National Center for Injury Prevention and Control July 2013.

9. Paulozzi LJ. Prescription drug overdoses: a review. *Journal of Safety Research,* 2012;43:283-289.

10. Dolan VF, Stout RL, Fulks M. [Mortality Associated with Positive Cocaine Test Results](http://www.crlcorp.com/wp-content/uploads/2013/06/otrcocainemortalityinapplicants2010_000.pdf). *On The Risk - Journal of the Academy of Life Underwriting*. 2010;26(1):46-52.

11. Dolan VF, Stout RL, Fulks M. [Improvements in Cotinine Testing of Insurance Applicants.](http://www.crlcorp.com/wp-content/uploads/2013/06/OTRStoutimprovementscotininetesting_001.pdf) *On The Risk - Journal of the Academy of Life Underwriting*. 2006;22(2):58-61.

12. Sadler G. Positive HIV, Cocaine and Cotinine Rates (2003) Insight a Publication of Lab*One*, Inc.

13. ENVOY 2003 Positive Cotinine Rates. A publication from Portamedic and Heritage Labs.

14. Clinical Reference Laboratory Annual Statistics for Insurance Applicant Samples (2012).

15. Clinical Reference Laboratory Annual Statistics for Insurance Applicant Samples (2013).

[[4]](#endnote-4)16. Dolan VF, Stout RL, Fulks M. [Non-Cigarette Tobacco Use – What Is the Risk?](http://www.crlcorp.com/wp-content/uploads/2013/06/OTRnon-cigtobaccouseJune2009_000.pdf) *On The Risk - Journal of the Academy of Life Underwriting*. 2009;25(2):56-9.

17. Stout RL Fulks M Vera F. Dolan, [Trends in Mortality of Insurance Applicants with HIV Infection.](http://www.crlcorp.com/wp-content/uploads/2013/06/JIM_Article_HIV_June_2012_20120730082553.pdf) *J Insur Med*. 2012;43:67-75.

18. Center for Disease Control, National Center for Infectious Diseases Viral Hepatitis Resource Center (2005) Sentinel Counties Study of Viral Hepatitis.

[[5]](#endnote-5)19. Atkins M, Nolan M Sexual transmission of hepatitis B. *Curr Opin Infect Dis*. 2005;18(1):67-72.

20. Bortolotti F, Jara P, Crivellaro C, Hierro L, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. *J Hepatol.* 1998;29(2):184-90.

21. Davis GL. Chronic hepatitis C and liver transplantation. *Rev Gastroenterol Disord.* 2004;4(1):7-17.

22. FDA approval of Sofosbuvir for the treatment of multiple genotypes of HCV. December 2013.

23. Dolan VF, Stout RL, Fulks M. [Mortality Associated with Positive Hepatitis C and B Results.](http://www.crlcorp.com/wp-content/uploads/2013/06/ILS-News-Document.pdf)

*On The Risk - Journal of the Academy of Life Underwriting*. 2010;26(3):68-71.

24. Fisher, MA, Ma ZQ. (2013). Multiple Chronic Conditions: Diabetes Associated With Comorbidity and Shared Risk Factors Using CDC WEAT and SAS Analytic Tools. *J Prim Care Community Health*. 2014;5:112-121.

25. Stout RL, Fulks M, Dolan VF, Magee ME, Suarez, L. Relationship of Hemoglobin A1c to Mortality in Nonsmoking Insurance Applicants. *J Insur Med*. 2007;39:174-81.

26. Dolan VF, Stout RL, Fulks M. Hemoglobin A1c and Mortality in Insurance Applicants: A 5-Year Follow-Up Study. *On The Risk - Journal of the Academy of Life Underwriting*. 2009;25(1):42-9.

27. Dolan VF, Fulks M, Stout RL. Using Urine Protein Creatinine Ratio Alone or Reflexing to Urine Albumin in the Applicant with HbA1c Elevation. *On The Risk - Journal of the Academy of Life Underwriting*. 2015;31(1):52-54.

28. Fulks M, Stout RL, Dolan VF. Using Liver Enzymes as Screening Tests to Predict Mortality Risk. *J Insur Med*. 2008;40:191-203.

29. Dolan VF, Stout RL, Fulks M. [CDT and Serum Alcohol: What Is the Risk?](http://www.crlcorp.com/wp-content/uploads/2013/06/otr-cdtandserumalcoholmortality2011.pdf) *On The Risk – Journal of the Academy of Life Underwriting*. 2011;27(1):45-48.

30. Duverger N, Rader D, Brewer HB. Distribution of subclasses of HDL containing apoA-1 without apoA-II (LpA-1) in normolipidemic men and women. *Arterioscler Thromb.* 1994;14(10):159-9.

31. Fulks M, Stout RL, Dolan VF. Letter to the Editor: Modeling Total Cholesterol as Predictor of Mortality – The Low-Cholesterol Paradox. *J Insur Med*. 2012;43(1):50.

32. Authors/Emerging Risk Factors Collaboration (ERFC) Writing Committee. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. *JAMA.* 2009;302(18):1993-2000.

33. Katsiki N, Athyros VG, Karagiannis A, et al. Metabolic Syndrome and Non-Cardiac Vascular Diseases: an Update from Human Studies. *Curr Pharm Des*. 2014;20:4944-52.

34. Clark M, Kaufman V, Fulks M, Dolan VF, Stout RL. NT-proBNP as a Predictor of All-Cause Mortality in a Population of Insurance Applicants. *J Insur Med.* 2014;44:7-16.

35. [Kilbride HS](http://www.ncbi.nlm.nih.gov/pubmed?term=Kilbride%20HS%5BAuthor%5D&cauthor=true&cauthor_uid=22889713), [Stevens PE](http://www.ncbi.nlm.nih.gov/pubmed?term=Stevens%20PE%5BAuthor%5D&cauthor=true&cauthor_uid=22889713), [Eaglestone G](http://www.ncbi.nlm.nih.gov/pubmed?term=Eaglestone%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22889713), et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. [*Am J Kidney Dis*.](http://www.ncbi.nlm.nih.gov/pubmed/22889713) 2013;61(1):57-66.

36. Fulks M, Dolan VF, Stout RL. Which eGFR Calculation Offers the Best Mortality Prediction for Insurance? *On The Risk - Journal of the Academy of Life Underwriting* 2015;31(2):58-61.

37. Fulks M, Stout RL, Dolan VF. Albumin and All-Cause Mortality Risk in Insurance Applicants. *J Insur Med*. 2010;42:11-17.

38. Fulks M, Stout RL, Dolan VF. [Mortality Associated with Bilirubin Levels in Insurance Applicants.](http://www.crlcorp.com/wp-content/uploads/2013/06/JIMbilirubinmortality2009_002.pdf) *J Insur Med*. 2008;41:49-53.

39. Fulks M, Stout RL, Dolan VF. Serum Globulin Predicts All-Cause Mortality for Life Insurance Applicants. *J. Insur. Med.* 2014;44:93-98.

40. Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. *Br J Haematol.* 2003;123(4):631-6.

41. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *J Clin Oncol*. 2002;20(6):1625-34.

42. Fulks M, Stout RL, Dolan VF. Hemoglobin Screening Independently Predicts All-Cause Mortality. *J. Insur. Med.* 2015;45:75-80.

43. Dolan VF, Stout RL, Fulks M. PSA: What Values Predict Increased Mortality Risk? *On The Risk - Journal of the Academy of Life Underwriting*. 2012;28(2):32-7.

44. Stout RL, Fulks M, Dolan VF, Magee ME, Suarez, L. Increased Mortality Associated with Elevated Carcinoembryonic Antigen in Insurance Applicants. *J Insur Med*. 2007;39:251-8.

45. Dolan VF, Stout RL, Fulks M. Underwriting Implications of Elevated Carcinoembryonic Antigen. *On The Risk - Journal of the Academy of Life Underwriting*. 2009;25(3):42-9.

46. Fulks M, Stout RL, Dolan VF. Scoring Life Insurance Applicants’ Laboratory Results, Blood Pressure and Build to Predict All-Cause Mortality Risk. *J Insur Med* 2012;43:169-177.

47. Palmier J. Lanzrath BJ. Individualized Mortality Projection and Product Pricing with Laboratory and Physical Measurements Data. *Product Matters*. June 2012:21-25.

1. [↑](#endnote-ref-1)
2. [↑](#endnote-ref-2)
3. [↑](#endnote-ref-3)
4. [↑](#endnote-ref-4)
5. [↑](#endnote-ref-5)